240 related articles for article (PubMed ID: 30321645)
1. HLA class II Eplet mismatch predicts De Novo DSA formation post lung transplant.
Walton DC; Cantwell L; Hiho S; Ta J; Wright S; Sullivan LC; Snell GI; Westall GP
Transpl Immunol; 2018 Dec; 51():73-75. PubMed ID: 30321645
[TBL] [Abstract][Full Text] [Related]
2. Eplet Mismatch Load and
Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
[TBL] [Abstract][Full Text] [Related]
3. Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: A new histocompatibility paradigm.
Bryan CF; Chadha V; Warady BA
Pediatr Transplant; 2016 Nov; 20(7):926-930. PubMed ID: 27448994
[TBL] [Abstract][Full Text] [Related]
4. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
[TBL] [Abstract][Full Text] [Related]
5. Impact of HLA Eplet Mismatch on De Novo Donor Specific Antibody Formation After Kidney Transplantation.
Yanyiam P; Kantachuvesiri S; Thammanichanond D
Transplant Proc; 2024 Apr; 56(3):515-520. PubMed ID: 38368130
[TBL] [Abstract][Full Text] [Related]
6. Analysis of T and B Cell Epitopes to Predict the Risk of
Sakamoto S; Iwasaki K; Tomosugi T; Niemann M; Spierings E; Miwa Y; Horimi K; Takeda A; Goto N; Narumi S; Watarai Y; Kobayashi T
Front Immunol; 2020; 11():2000. PubMed ID: 32973806
[TBL] [Abstract][Full Text] [Related]
7. Degree of HLA class II eplet mismatch load improves prediction of antibody-mediated rejection in living donor kidney transplantation.
Tafulo S; Malheiro J; Santos S; Dias L; Almeida M; Martins S; Pedroso S; Mendes C; Lobato L; Castro-Henriques A
Hum Immunol; 2019 Dec; 80(12):966-975. PubMed ID: 31604581
[TBL] [Abstract][Full Text] [Related]
8. HLA Matching at the Eplet Level Protects Against Chronic Lung Allograft Dysfunction.
Walton DC; Hiho SJ; Cantwell LS; Diviney MB; Wright ST; Snell GI; Paraskeva MA; Westall GP
Am J Transplant; 2016 Sep; 16(9):2695-703. PubMed ID: 27002311
[TBL] [Abstract][Full Text] [Related]
9. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
[TBL] [Abstract][Full Text] [Related]
10. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen eplet mismatching is associated with increased risk of graft loss and rejection after pediatric heart transplant.
Albers EL; Friedland-Little JM; Hong BJ; Kemna MS; Warner P; Law YM
Pediatr Transplant; 2022 Feb; 26(1):e14126. PubMed ID: 34476876
[TBL] [Abstract][Full Text] [Related]
12. Eplet mismatch analysis and allograft outcome across racially diverse groups in a pediatric transplant cohort: a single-center analysis.
Philogene MC; Amin A; Zhou S; Charnaya O; Vega R; Desai N; Neu AM; Pruette CS
Pediatr Nephrol; 2020 Jan; 35(1):83-94. PubMed ID: 31599339
[TBL] [Abstract][Full Text] [Related]
13. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
[TBL] [Abstract][Full Text] [Related]
14. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
[TBL] [Abstract][Full Text] [Related]
15. HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients.
Zhang X; Kransdorf E; Levine R; Patel JK; Kobashigawa JA
Hum Immunol; 2020 Jul; 81(7):330-336. PubMed ID: 32307126
[TBL] [Abstract][Full Text] [Related]
16. Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?
Wen J; Basu A; Bentall A; Henderson N; Dukek B; Gandhi M; Schinstock C
Hum Immunol; 2021 Apr; 82(4):240-246. PubMed ID: 33618904
[TBL] [Abstract][Full Text] [Related]
17. Comparison of human leukocyte antigen immunologic risk stratification methods in lung transplantation.
Hiho SJ; Levvey BJ; Diviney MB; Snell GI; Sullivan LC; Westall GP
Am J Transplant; 2024 May; 24(5):827-838. PubMed ID: 37981213
[TBL] [Abstract][Full Text] [Related]
18. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA.
Jucaud V
J Immunol Res; 2017; 2017():2748614. PubMed ID: 28331856
[TBL] [Abstract][Full Text] [Related]
19. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study.
Sapir-Pichhadze R; Tinckam K; Quach K; Logan AG; Laupacis A; John R; Beyene J; Kim SJ
Am J Transplant; 2015 Jan; 15(1):137-48. PubMed ID: 25521856
[TBL] [Abstract][Full Text] [Related]
20. Epitope analysis of HLA-DQ antigens: what does the antibody see?
Tambur AR; Rosati J; Roitberg S; Glotz D; Friedewald JJ; Leventhal JR
Transplantation; 2014 Jul; 98(2):157-66. PubMed ID: 25003284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
